147 related articles for article (PubMed ID: 34703008)
1. Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
Ouahoud S; Jacobs RJ; Kodach LL; Voorneveld PW; Hawinkels LJAC; Weil NL; van Vliet B; Herings RM; van der Burg LRA; van Wezel T; Morreau H; Slingerland M; Bastiaannet E; Putter H; Hardwick JCH
Br J Cancer; 2022 Feb; 126(2):297-301. PubMed ID: 34703008
[TBL] [Abstract][Full Text] [Related]
2. Statin Use After Diagnosis of Colon Cancer and Patient Survival.
Voorneveld PW; Reimers MS; Bastiaannet E; Jacobs RJ; van Eijk R; Zanders MMJ; Herings RMC; van Herk-Sukel MPP; Kodach LL; van Wezel T; Kuppen PJK; Morreau H; van de Velde CJH; Hardwick JCH; Liefers GJ
Gastroenterology; 2017 Aug; 153(2):470-479.e4. PubMed ID: 28512021
[TBL] [Abstract][Full Text] [Related]
3. Mutation Status of
Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
5. Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study.
Krens LL; Simkens LH; Baas JM; Koomen ER; Gelderblom H; Punt CJ; Guchelaar HJ
PLoS One; 2014; 9(11):e112201. PubMed ID: 25375154
[TBL] [Abstract][Full Text] [Related]
6. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
8.
Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
[No Abstract] [Full Text] [Related]
9. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
Lieu CH; Golemis EA; Serebriiskii IG; Newberg J; Hemmerich A; Connelly C; Messersmith WA; Eng C; Eckhardt SG; Frampton G; Cooke M; Meyer JE
Clin Cancer Res; 2019 Oct; 25(19):5852-5858. PubMed ID: 31243121
[TBL] [Abstract][Full Text] [Related]
10. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
11. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
Gray RT; Loughrey MB; Bankhead P; Cardwell CR; McQuaid S; O'Neill RF; Arthur K; Bingham V; McGready C; Gavin AT; James JA; Hamilton PW; Salto-Tellez M; Murray LJ; Coleman HG
Br J Cancer; 2017 Jun; 116(12):1652-1659. PubMed ID: 28524155
[TBL] [Abstract][Full Text] [Related]
12. Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- but not BRAF+ colorectal cancer.
Jayasekara H; MacInnis RJ; Williamson EJ; Hodge AM; Clendenning M; Rosty C; Walters R; Room R; Southey MC; Jenkins MA; Milne RL; Hopper JL; Giles GG; Buchanan DD; English DR
Int J Cancer; 2017 Apr; 140(7):1485-1493. PubMed ID: 27943267
[TBL] [Abstract][Full Text] [Related]
13. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
14. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.
Lee JE; Baba Y; Ng K; Giovannucci E; Fuchs CS; Ogino S; Chan AT
Cancer Prev Res (Phila); 2011 Nov; 4(11):1808-15. PubMed ID: 21680706
[TBL] [Abstract][Full Text] [Related]
15. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
16. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status.
Inamura K; Song M; Jung S; Nishihara R; Yamauchi M; Lochhead P; Qian ZR; Kim SA; Mima K; Sukawa Y; Masuda A; Imamura Y; Zhang X; Pollak MN; Mantzoros CS; Harris CC; Giovannucci E; Fuchs CS; Cho E; Chan AT; Wu K; Ogino S
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598515
[TBL] [Abstract][Full Text] [Related]
17. Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
Susanti S; Fadhil W; Murtaza S; Hassall JC; Ebili HO; Oniscu A; Ilyas M
J Clin Pathol; 2019 Mar; 72(3):263-264. PubMed ID: 30361395
[No Abstract] [Full Text] [Related]
18. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
19. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
